echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Epilepsia: To compare the prognosis of MRgLITT with open surgery for drug-refractory epilepsy

    Epilepsia: To compare the prognosis of MRgLITT with open surgery for drug-refractory epilepsy

    • Last Update: 2022-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Minimally invasive magnetic resonance-guided laser interstitial hyperthermia (MRgLITT) has been proposed as an alternative to open epilepsy surgery to address questions
    about the risks of open surgery.
    The journal Epilepsia published a study with the primary objective of comparing MRgLITT with open surgery in children with
    drug-refractory epilepsy (DRE).
    Secondary objectives were to compare complications and length
    of hospital stay between the two treatments.

    This retrospective multicenter cohort study included children with DRE treated with MRgLITT or open surgery with 1 year
    follow-up.
    Exclusion criteria were corpus callosotomy, nerve stimulation, multilobar or hemispherical surgery, and lesions
    with a maximum size greater than 60 mm.
    MRgLITT tends to be matched
    with open surgery patients.
    The primary outcome was seizure-free
    for one year after treatment.
    The non-inferiority test was used to compare the difference in seizure-free with a cut-off of -10%.

    Secondary outcomes were complications and length of
    hospital stay.

    185 MRgLITT patients were matched with
    185 patients with open surgery.
    In the matching cohort, the mean ages of MRgLITT and surgical patients were 11.
    3±4.
    8 and 11.
    0±5.
    0 years
    , respectively.

    At 1-year follow-up, 89/185 (48.
    1%) patients with MRgLITT and 114/185 (61.
    6%) patients with open surgery were seizure-free (difference = -13.
    5%, unilateral 97.
    5% CI: -23.
    8% to ∞, P non-inferiority = 0.
    79).

    The lower bound of the confidence interval is -23.
    8%, which is lower than the predetermined non-inferiority cut-off of -10%.

    Compared with open surgery, MRgLITT was significantly lower associated
    with cortical developmental malformations without seizures (26/60 (43.
    3%) vs 46/60 (76.
    7%), p < 0.
    001) and 20~40 mm lesion size (24/65 (36.
    9%) vs 38/60 (63.
    3%), p = 0.
    006, respectively).
    。 After MRgLIT, temporal lobe epilepsy (40/77 (51.
    9%) vs 54/81 (66.
    7%), p = 0.
    09), extratemporal lobe epilepsy (49/108 (45.
    4%) vs 60/104 (57.
    7%), p = 0.
    10), hippocampal sclerosis (15/32 (46.
    9%) vs 25/35 (71.
    4%), p = 0.
    07), tumor (14/20 (70.
    0%), respectively Seizure-free rates were lower but not statistically significant,
    with lesion size ≤ 20 mm (58/108 (53.
    7%), p = 0.
    47), and lesion size > 40 mm (7/12 (58.
    3%), vs 12/17 (70.
    6%), p = 0.
    77, respectively.

    The overall complication rate of MRgLITT was lower than that of open surgery (10.
    8 versus 29.
    2 percent, p < 0.
    001).

    MRgLITT had a shorter hospital stay than open surgery (3.
    1±2.
    9 vs 7.
    2±6.
    1 days, p < 0.
    001).

    After 1 year of treatment, MRgLITT had a worse seizure outcome than open surgery
    .
    However, MRgLITT has a better safety profile and shorter hospital
    stay.
    The findings will help inform children and parents about the benefits and risks of MRgLITT and help make informed decisions
    about treatment options.

    Original source:

    Omar Yossofzai, Scellig Stone, et al, Seizure Outcome of Pediatric MR-guided Laser Interstitial Thermal Therapy versus Open Surgery: A Matched Non-Inferiority Cohort Study, Epilepsia, 2022, https://doi.
    org/10.
    1111/epi.
    17451.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.